Mariner’s Contineum Therapeutics CTNM Stock Holding History

Mariner’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,420	Closed	-$122K	–	3840
2025 Q3	$122K	Buy	+10,420	New	+$84K	﹤0.01%	3320

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mariner's CTNM Position: Q4 2025 in Review

Mariner sold out of Contineum Therapeutics (CTNM) in Q4 2025, closing a stake of 10,420 shares — an estimated $122K sold.

Mariner first reported a position in CTNM in Q3 2025 and held it in 1 quarter. The position peaked at $122K in Q3 2025. 80 funds tracked by Wall St. Rank hold CTNM as of Q4 2025.

Mariner reported no remaining Contineum Therapeutics position as of Q4 2025 after selling out during the quarter.
Mariner sold 10,420 Contineum Therapeutics shares in Q4 2025, an estimated $122K.
Mariner first reported a position in Contineum Therapeutics in Q3 2025 and held it in 1 quarter.
Mariner's Contineum Therapeutics position peaked at $122K in Q3 2025.
80 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.